AU
UK
CA
NZ
IND
US
Last update at 2026-06-05T20:27:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential
Tue 20 May 25, 05:52 PMAutolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
Fri 17 Jan 25, 12:00 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
| Income before tax | -296.84808M | -219.13400M | -208.40200M | -148.56700M | -173.20500M |
| Minority interest | - | - | - | - | - |
| Net income | -287.52800M | -220.66200M | -208.38300M | -148.83900M | -148.83900M |
| Selling general administrative | 131.87M | 101.09M | 46.74M | 31.90M | 31.90M |
| Selling and marketing expenses | - | - | 1.10M | - | - |
| Gross profit | -21.03003M | -130.90000M | 1.70M | 6.19M | 6.19M |
| Reconciled depreciation | 9.81M | 7.72M | 6.44M | 7.42M | 7.42M |
| Ebit | -281.43715M | -240.78900M | -163.33500M | -139.66200M | -163.78500M |
| Ebitda | -271.60021M | -233.07300M | -156.77000M | -132.24000M | -156.36300M |
| Depreciation and amortization | 9.84M | 7.72M | 6.57M | 7.42M | 7.42M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -281.43715M | -241.42600M | -179.70100M | -142.89300M | -163.78500M |
| Other operating expenses | 357.00M | 251.55M | 181.40M | 149.09M | 173.72M |
| Interest expense | 36.76M | 9.29M | 45.07M | 8.90M | 8.90M |
| Tax provision | 1.97M | 1.53M | -17.49600M | -24.36600M | -24.36600M |
| Interest income | 18.98M | 32.35M | 11.92M | 1.71M | 1.71M |
| Net interest income | -17.69000M | 23.06M | -6.47500M | -7.19700M | -7.19700M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.97M | 1.53M | -0.01900M | 0.27M | -24.36600M |
| Total revenue | 75.56M | 10.12M | 1.70M | 6.19M | 6.19M |
| Total operating expenses | 260.41M | 110.53M | 181.40M | 149.09M | 173.72M |
| Cost of revenue | 96.37M | 141.02M | 6.57M | 137.22M | - |
| Total other income expense net | -15.41093M | 22.29M | -28.70100M | -5.67400M | -9.42000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -287.52800M | -220.66200M | -158.16300M | -148.83900M | -148.83900M |
| Net income applicable to common shares | - | - | - | -148.83900M | -148.83900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-09-30 | 2022-12-31 |
| Total assets | 589.07M | 782.73M | 375.38M | 375.38M | 490.27M |
| Intangible assets | 19.81M | 12.37M | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 26.74M | 20.53M | 34.69M | 35.74M | 14.36M |
| Total liab | 410.94M | 355.40M | 263.91M | 263.91M | 191.60M |
| Total stockholder equity | 178.13M | 427.32M | 111.47M | 111.47M | 298.67M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 55.79M | 52.18M | 39.58M | 44.74M | 40.80M |
| Common stock | 0.01M | 0.01M | 0.00800M | 0.00800M | 0.00800M |
| Capital stock | 0.01M | 0.01M | 0.00800M | 0.00800M | 0.00800M |
| Retained earnings | -1386.75200M | -1099.22400M | -878.56200M | -878.56200M | -670.17900M |
| Other liab | - | - | - | - | 126.02M |
| Good will | - | - | - | - | - |
| Other assets | - | - | 0.00000M | 0.00000M | 6.08M |
| Cash | 104.13M | 227.38M | 239.57M | 239.57M | 382.44M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 73.44M | 60.74M | 44.74M | 44.74M | 46.37M |
| Current deferred revenue | - | - | -5.15600M | -5.15600M | - |
| Net debt | 247.45M | -174.75100M | -186.59900M | -186.59900M | -358.18000M |
| Short term debt | 14.56M | 3.00M | 5.05M | 5.05M | 5.04M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 351.59M | 52.63M | 52.97M | 52.97M | 24.26M |
| Other stockholder equity | 1570.11M | 1555.71M | 1019.02M | 1019.02M | 1007.74M |
| Property plant equipment | - | - | - | - | 58.42M |
| Total current assets | 435.92M | 660.93M | 275.30M | 275.30M | 425.77M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | 298.67M |
| Short term investments | 196.58M | 360.64M | 0.00000M | - | - |
| Net receivables | 75.26M | 48.24M | 1.05M | 24.54M | 28.98M |
| Long term debt | - | - | - | - | - |
| Inventory | 33.21M | 4.14M | -23.49500M | -24.54200M | 14.16M |
| Accounts payable | 3.08M | 1.97M | 0.10M | 0.10M | 0.53M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -5.35600M | -29.17400M | -28.99200M | -28.99200M | -38.89800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1.28M | 1.13M | 1.36M | 1.36M | 4.01M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 153.15M | 121.80M | 100.08M | 100.08M | 64.50M |
| Capital lease obligations | 71.39M | 52.63M | 52.97M | 52.97M | 24.26M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2022-09-30 |
| Investments | 185.59M | -394.55200M | -10.98600M | -10.84100M | -10.84100M |
| Change to liabilities | - | - | - | 0.02M | 0.02M |
| Total cashflows from investing activities | 158.46M | -394.55200M | -10.98600M | -10.84100M | -10.84100M |
| Net borrowings | - | - | - | - | - |
| Total cash from financing activities | -4.33900M | 589.55M | -0.88300M | 223.61M | 223.61M |
| Change to operating activities | - | - | - | 3.95M | 3.95M |
| Net income | -287.52800M | -220.66200M | -208.38300M | -148.83900M | -148.83900M |
| Change in cash | -123.17000M | -11.53000M | -142.42600M | 72.08M | 72.08M |
| Begin period cash flow | 228.81M | 240.34M | 382.76M | 310.68M | 310.68M |
| End period cash flow | 105.64M | 228.81M | 240.34M | 382.76M | 382.76M |
| Total cash from operating activities | -283.56800M | -206.27100M | -145.58700M | -112.30800M | -112.30800M |
| Issuance of capital stock | 0.00000M | 549.98M | 0.00000M | 163.85M | 163.85M |
| Depreciation | 9.81M | 7.72M | 6.57M | 7.42M | 7.42M |
| Other cashflows from investing activities | -27.13200M | -12.74400M | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -40.34406M | -4.22900M | 0.00000M | - | - |
| Change to account receivables | -24.21445M | 0.00000M | - | - | - |
| Sale purchase of stock | - | - | - | - | - |
| Other cashflows from financing activities | -4.33900M | 39.58M | -0.88300M | 59.76M | 59.76M |
| Change to netincome | - | - | - | 25.14M | 25.14M |
| Capital expenditures | 19.09M | 34.82M | 10.99M | 10.84M | 10.84M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -52.11049M | -23.65500M | 0.29M | 3.97M | 3.97M |
| Stock based compensation | 14.44M | 15.47M | 11.20M | 12.01M | 12.01M |
| Other non cash items | 32.10M | 15.04M | 45.72M | 13.39M | 13.39M |
| Free cash flow | -303.31816M | -241.09000M | -156.57300M | -123.14900M | -123.14900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AUTL Autolus Therapeutics Ltd |
-0.13 7.83% | 1.53 | - | - | 382.50 | 2.38 | 2.57 | 0.03 |
| NVO Novo Nordisk A/S |
-0.79 1.81% | 42.96 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.6937 1.57% | 43.50 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.09 1.15% | 446.83 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.72 1.07% | 635.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
The Mediaworks, London, United Kingdom, W12 7FP
| Name | Title | Year Born |
|---|---|---|
| Dr. Christian Martin Itin Ph.D. | CEO & Director | 1964 |
| Dr. Martin Pule M.D., MBBS | Founder, Sr. VP & Chief Scientific Officer | 1972 |
| Mr. Christopher Vann | Sr. VP & COO | 1965 |
| Mr. David Brochu | Sr. VP & Chief Technical Officer | 1956 |
| Mr. Andrew J. Oakley ACA, BEcon, MBA | Sr. Advisor | 1962 |
| Mr. Brent Rice | Sr. VP, Chief Commercial Officer & Site Head of US | 1966 |
| Dr. Edgar E. W. Braendle M.D., Ph.D. | Sr. VP & Chief Devel. Officer | 1960 |
| Dr. Lucinda Crabtree Ph.D. | Chief Financial Officer | NA |
| Ms. Olivia Manser | Director of Investor Relations | NA |
| Dr. Chris Williams | Sr. VP of Corp. Devel. | 1980 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...